Compare CUZ & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CUZ | EWTX |
|---|---|---|
| Founded | 1958 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.3B |
| IPO Year | 1994 | 2021 |
| Metric | CUZ | EWTX |
|---|---|---|
| Price | $22.60 | $33.01 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 6 |
| Target Price | $28.33 | ★ $39.00 |
| AVG Volume (30 Days) | ★ 1.6M | 762.4K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.76% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $993,816,000.00 | N/A |
| Revenue This Year | $4.19 | N/A |
| Revenue Next Year | $3.89 | N/A |
| P/E Ratio | $92.48 | ★ N/A |
| Revenue Growth | ★ 16.00 | N/A |
| 52 Week Low | $21.03 | $11.23 |
| 52 Week High | $30.80 | $34.00 |
| Indicator | CUZ | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.89 | 61.54 |
| Support Level | $21.11 | $28.72 |
| Resistance Level | $23.33 | N/A |
| Average True Range (ATR) | 0.73 | 1.46 |
| MACD | 0.11 | 0.21 |
| Stochastic Oscillator | 58.52 | 82.26 |
Cousins Properties Inc is a real estate investment trust principally involved in the ownership, management, and development of properties in the Southern United States. Cousins Properties' real estate portfolio mainly comprises offices and mixed-use developments that encompass both apartment and retail space. Offices make up the vast majority of the portfolio in terms of total square footage. The segments operates in following geographical areas: Atlanta, Austin, Charlotte, Dallas, Phoenix, Tampa, and other markets. The company derives nearly all of its revenue in the form of rental income from its properties, the majority of which comes from its office locations. A diverse set of tenants in the cities of Houston and Atlanta represent the company's key markets.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.